ImmunityBio
IBRX
139 hedge funds and large institutions have $256M invested in ImmunityBio in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 11 closing their positions.
136% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 11
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
30% more capital invested
Capital invested by funds: $196M → $256M (+$59.7M)
10% more funds holding
Funds holding: 126 → 139 (+13)
2.35% more ownership
Funds ownership: 9.86% → 12.21% (+2.4%)
5% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 41
22% less call options, than puts
Call options by funds: $3.69M | Put options by funds: $4.76M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$41.8M |
| 2 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
+$7.34M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.66M |
| 4 |
BlackRock
New York
|
+$4.41M |
| 5 |
Goldman Sachs
New York
|
+$3.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$3.37M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.17M |
| 3 |
Millennium Management
New York
|
-$1.98M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.57M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.15M |
IBRX Hedge Fund Activity: Q4 2022 in Review
139 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q4 2022, worth a combined $256M — up 30% from $196M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new IBRX positions and 11 closed out — a net gain of 15 holders — while 43 added to existing stakes and 41 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $41.8M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $3.37M sold.
- 139 institutional investors held ImmunityBio (IBRX) as of Q4 2022, up from 126 in Q3 2022.
- Funds reported $256M of ImmunityBio stock for Q4 2022, up 30% quarter-over-quarter.
- 26 funds opened new ImmunityBio positions in Q4 2022 and 11 closed out, a net change of +15 holders.
- The largest ImmunityBio buyer in Q4 2022 was CVI Holdings, an estimated $41.8M added.
- The largest ImmunityBio seller in Q4 2022 was D.E. Shaw & Co, an estimated $3.37M sold.
Based on aggregated 13F filings for Q4 2022.